Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation
Prophylaxis Roles of Low Dose of IL-2 Treatment on GVHD After Haploidentical Transplantation
Sponsor: Peking University People's Hospital
A PHASE2 clinical study on Acute Graft-versus-host Disease, this trial is ongoing. The trial is conducted by Peking University People's Hospital and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jul 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jul 2020 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2020 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .